Matthew P. Goetz, M.D.
Professor of Oncology and Pharmacology
Chief, Mayo Clinic Breast Cancer Disease Group
Co-leader, Mayo Clinic Women's Cancer Program
Co-Director, Mayo Clinic Breast Cancer SPORE

Locations:

• Geffen Auditorium (Live)
• Broadcast to SMH Alfred M-459 and MA 17-64
• Mayo Clinic Health System in Waycross (Video Conference)

Lunch available outside Geffen Auditorium and SMH Alfred M-459 on a first come, first serve basis

Learning Objectives:

• Review the natural history of estrogen receptor (ER) positive breast cancer and define the impact of adjuvant hormonal therapies on the survival of women with early stage ER+ breast cancer
• Identify critical host and tumor factors that drive resistance to ER targeted therapies
• Identify new FDA approved therapies and their impact on preventing the progression of metastatic ER positive breast cancer

  
  Financial Disclosure:

• Consultant - Eli Lilly, Genomic Health Innovations
• Grant/Research Support - Eli Lilly and Pfizer

Off Label/Investigational Uses:

• None

Accreditation Statement

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA

The Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here to review disclosures.